OTLK

Outlook Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website outlooktherapeutics.com
Employees(FY) 24
ISIN US69012T3059

Performance

+0.65%

1W

-11.09%

1M

-13.86%

3M

-10.86%

6M

-1.27%

YTD

-67.58%

1Y

Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Advanced Technical Analysis

Technical Analysis of OTLK 2024-05-10

Overview:

In analyzing the technical indicators for OTLK over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Indicators:

Moving Averages (MA): The 5-day MA has been consistently below the closing prices, ...

See more ...

Recent News & Updates

2024-05-16 16:27
Q2 2024 Outlook Therapeutics Inc Earnings Call(Yahoo Finance)
2024-05-15 10:53
OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024(Investorplace)
2024-05-15 05:00
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update(Globenewswire)
2024-05-12 23:18
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK(Yahoo Finance)
2024-05-12 20:50
Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD(Globenewswire)
2024-05-08 20:45
Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast(Globenewswire)
2024-05-01 21:05
Outlook Therapeutics to Present at the Retina World Congress 2024(Globenewswire)
2024-04-28 21:00
Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase(Globenewswire)
2024-04-25 18:37
Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors(Yahoo Finance)
2024-04-15 04:15
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million(Globenewswire)
2024-04-15 00:54
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential(Yahoo Finance)
2024-04-10 03:30
Insiders are Piling into These 10 Healthcare Stocks in 2024(Insidermonkey)
2024-03-21 19:35
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD(Globenewswire)
2024-03-18 05:10
Outlook Therapeutics Announces Closing of Private Placement of up to $159 Million(Globenewswire)
2024-03-12 08:05
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split(GlobeNewswire)
2024-03-11 20:05
Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split(Globenewswire)
2024-03-06 02:36
7 of the Best Speculative Stocks You Can Snag for Less Than $1(Yahoo Finance)
2024-02-25 00:37
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory(Yahoo Finance)
2024-02-14 08:05
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update(GlobeNewswire)
2024-02-14 04:27
Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments(Yahoo Finance)
2024-02-13 19:05
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update(Globenewswire)
2024-01-31 08:05
Outlook Therapeutics® Doses First Subject in NORSE EIGHT(GlobeNewswire)
2024-01-30 19:05
Outlook Therapeutics Doses First Subject in NORSE EIGHT(Globenewswire)
2024-01-23 19:06
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study(Yahoo Finance)
2024-01-23 08:00
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010(GlobeNewswire)
2024-01-22 19:00
Outlook Therapeutics Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010(Globenewswire)
2024-01-02 09:18
Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm(Globenewswire)
2023-12-27 01:03
OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023(Investorplace)
2023-12-26 20:30
OUTLOOK SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options(Globenewswire)
2023-12-26 01:15
January 2. 2024 Lawsuit Deadline: Investors who lost over $200,000 with Outlook Therapeutics, Inc. (NASDAQ: OTLK) shares should contact the Shareholders Foundation(Globenewswire)

Page 1 of 5

previousnext